Proposed Collection; 60-Day Comment Request; Application for Collaboration With the Therapeutic Development Branch (TDB), Division of Preclinical Innovation (DPI), National Center for Advancing Translational Sciences (NCATS), 69499-69500 [2014-27636]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 225 / Friday, November 21, 2014 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Chapter RV—HIV/AIDS Bureau
Health Resources and Services
Administration
Delete the functions for the Division
of HIV/AIDS Training and Capacity
Development (RV7) within the HIV/
AIDS Bureau (RV) and replace in its
entirety.
Section RV–20, Functions
Statement of Organization, Functions
and Delegations of Authority
This notice amends Part R of the
Statement of Organization, Functions
and Delegations of Authority of the
Department of Health and Human
Services (HHS), Health Resources and
Services Administration (HRSA) (60 FR
56605, as amended November 6, 1995;
as last amended at 79 FR 63412–63414
dated October 23, 2014).
This notice reflects organizational
changes in the Health Resources and
Services Administration (HRSA).
Specifically, this notice abolishes the
Division of Global Training and
Development and transfers the Global
Health Workforce Training Programs
from the Bureau of Health Workforce
(RQ) to the HIV/AIDS Bureau (RV).
Chapter RQ—Bureau of Health
Workforce
Section RQ–20, Functions
Delete the functions for the Office of
Global Health Affairs (RQA1) within the
Bureau of Health Workforce (RQ) and
replace in its entirety.
mstockstill on DSK4VPTVN1PROD with NOTICES
Office of Global Health Affairs (RQA1)
The Office of Global Health Affairs
serves as the principal advisor to the
Office of Workforce Development and
Analysis Director and the Associate
Administrator on global health issues.
Specifically: (1) Provides leadership,
coordination, and advancement of
global health activities relating to health
care services for vulnerable and at-risk
populations and for HRSA training
programs; (2) provides support for the
agency’s International Visitors Program;
(3) develops linkages and facilitates a
mutual exchange of expertise for
domestic and international programs
aimed at improving quality and
innovation in health professions
education, retention, training, faculty
development and community based
systems of care; (4) provides leadership
within HRSA for the support of global
health and coordinates policy
development with the HHS Office of
Global Health Affairs and other
departmental agencies, and; (5) supports
and conducts programs with respect to
activities associated with the
international migration, domestic
training, and utilization of foreign
medical graduates and U.S. citizens
studying abroad.
VerDate Sep<11>2014
18:00 Nov 20, 2014
Jkt 235001
Division of HIV/AIDS Training and
Capacity Development (RV7)
The Division of HIV/AIDS Training
and Capacity Development provides
national leadership and manages the
implementation of Part F under Title
XXVI of the PHS Act as amended by the
Ryan White HIV/AIDS Treatment
Extension Act of 2009, P.L. 111–87 (the
Ryan White HIV/AIDS Program),
including the Special Projects of
National Significance and the AIDS
Education and Training Centers
Programs. The Special Projects of
National Significance Program develops
innovative models of HIV care and the
AIDS Education and Training Centers
Program increases the number of health
care providers who are educated and
motivated to counsel, diagnose, treat,
and medically manage people with HIV
disease and to help prevent high-risk
behaviors that lead to HIV transmission.
The division also implements the
training and systems strengthening
functions of the Global HIV/AIDS
Program as part of the President’s
Emergency Plan for AIDS Relief
(PEPFAR). This includes strengthening
health systems for delivery of
prevention, care and treatment services
for people living with HIV/AIDS in
PEPFAR funded countries and
providing management and oversight of
international programs aimed at
improving quality and innovation in
health professions education and
training. The division will translate
lessons learned from both the Global
HIV/AIDS Programs and Special
Projects of National Significance
projects to the Part A, B, C, D, and F
grantee community. In collaboration
with the Division of Policy and Data, the
division assesses effectiveness of
technical assistance efforts/initiatives,
identifies new technical assistance
needs and priority areas, and
participates in the bureau-wide
technical assistance workgroup.
Section RV–30, Delegations of Authority
All delegations of authority and redelegations of authority made to HRSA
officials that were in effect immediately
prior to this reorganization, and that are
consistent with this reorganization,
shall continue in effect pending further
re-delegation.
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
69499
This reorganization is effective upon
date of signature.
Dated: November 16, 2014.
Mary K. Wakefield,
Administrator.
[FR Doc. 2014–27563 Filed 11–20–14; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-Day Comment
Request; Application for Collaboration
With the Therapeutic Development
Branch (TDB), Division of Preclinical
Innovation (DPI), National Center for
Advancing Translational Sciences
(NCATS)
Summary: In compliance with the
requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
for opportunity for public comment on
proposed data collection projects, the
National Center for Advancing
Translational Sciences (NCATS),
National Institutes of Health (NIH), will
publish periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
Written comments and/or suggestions
from the public and affected agencies
are invited on one or more of the
following points: (1) Whether the
proposed collection of information is
necessary for the proper performance of
the function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
Ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) Ways to minimize the
burden of the collection of information
on those who are to respond, including
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology.
To Submit Comments and for Further
Information: To obtain a copy of the
data collection plans and instruments,
submit comments in writing, or request
more information on the proposed
project, contact: Dr. Nora Yang,
Therapeutic Development Branch, DPI,
NCATS, NIH, 9800 Medical Center
Drive, Building B, Rockville, MD 20850,
or call non-toll-free number (301) 217–
1077, or Email your request, including
your address to: TRND@mail.nih.gov.
Formal requests for additional plans and
E:\FR\FM\21NON1.SGM
21NON1
69500
Federal Register / Vol. 79, No. 225 / Friday, November 21, 2014 / Notices
instruments must be requested in
writing.
Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Proposed Collection: Application for
Collaboration with the Therapeutic
Development Branch (TDB), Division of
Preclinical Innovation (DPI), National
Center for Advancing Translational
Sciences (NCATS), 0925–0658,
Expiration Date 06/30/2015—
EXTENSION, National Center for
Advancing Translational Sciences
diseases. The TDB uses an application
and evaluation process to select
collaborators. Selected investigators
provide the drug project starting points
and ongoing biological/disease expertise
throughout the project. The application
and evaluation process is necessary to
determine amount and quality of
current data, select meritorious projects
for adoption, and to serve as a basis for
determining specific scientific gaps to
be filled.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The estimated
annualized burden hours are 510.
(NCATS), National Institutes of Health
(NIH).
Need and Use of Information
Collection: The Therapeutic
Development Branch (TDB) provides
opportunities to partner with and gain
access to a variety of programs
delivering assay development,
screening, hit-to-lead chemistry, lead
optimization, chemical biology studies,
drug development capabilities,
expertise, and clinical/regulatory
resources in a collaborative
environment, with the goal of moving
promising therapeutics into human
clinical trials for both common and
specifically rare and/or neglected
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Form name
TDB Project Information Template ..................................................................
Online Collaborator Solicitation (TRND) ..........................................................
Online Collaborator Solicitation (BrIDGs) ........................................................
Solicitation Instructions (TRND) .......................................................................
Solicitation Instructions (BrIDGs) .....................................................................
Dated: October 29, 2014.
M. Janis Mullaney,
Associate Director for Administration,
NCATS, NIH.
[FR Doc. 2014–27636 Filed 11–20–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
mstockstill on DSK4VPTVN1PROD with NOTICES
Proposed Collection; 60-Day Comment
Request; Generic Clearance for the
Collection of Qualitative Feedback on
Agency Service Delivery (NIH)
Summary: The National Institutes of
Health (NIH), Office of the Director
(OD), as part of its continuing effort to
reduce paperwork and respondent
burden, invites the general public to
take this opportunity to comment on the
‘‘Generic Clearance for the Collection of
Qualitative Feedback on Agency Service
Delivery ’’ for approval under the
Paperwork Reduction Act (PRA) (44
U.S.C. 3501 et. seq.). This collection was
developed as part of a Federal
Government-wide effort to streamline
the process for seeking feedback from
the public on service delivery. This
notice announces our intent to submit
this collection to OMB for approval and
solicits comments on specific aspects
for the proposed information collection.
VerDate Sep<11>2014
18:00 Nov 20, 2014
Jkt 235001
170
100
70
100
70
To Submit Comments and for Further
Information: To obtain a copy of the
data collection plans and instruments,
submit comments in writing, or request
more information on the proposed
project, contact: Ms. Mikia P. Currie,
Program Analyst, Office of Policy for
Extramural Research Administration,
6705 Rockledge Drive, Suite 350,
Bethesda, Maryland 20892, or call a
non-toll-free number 301–435–0941 or
Email your request, including your
address to curriem@mail.nih.gov.
Formal requests for additional plans and
instruments must be requested in
writing.
Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Proposed Collection: Generic
Clearance for the Collection of
Qualitative Feedback on Agency Service
Delivery (NIH), 0925–0648, Expiration
Date 1/31/2015, EXTENSION, National
Institutes of Health (NIH), Office of the
Director (OD).
Need and Use of Information
Collection: We are not requesting
changes for this submission. The
proposed information collection activity
provides a means to garner qualitative
customer and stakeholder feedback in
an efficient, timely manner, in
accordance with the Administration’s
commitment to improving service
delivery. By qualitative feedback we
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
1
1
1
1
1
Average
burden per
response
(in hours)
Total annual
burden hour
1
1
1
1
1
170
100
70
100
70
mean information that provides useful
insights on perceptions and opinions.
This information, however, is not
statistical surveys that yield quantitative
results, which can be generalized to the
population of study. This feedback will
provide information about the NIH’s
customer or stakeholder perceptions,
experiences, and expectations, provide
an early warning of issues with service,
or focus attention on areas where
communication, training, or changes in
operations might improve delivery of
products or services. These collections
will allow for ongoing, collaborative,
and actionable communications
between the NIH and its customers and
stakeholders. It will also allow feedback
to contribute directly to the
improvement of program management.
The solicitation of feedback will target
areas such as: timeliness,
appropriateness, accuracy of
information, courtesy, efficiency of
service delivery, and resolution of
issues with service delivery. Responses
will be assessed to plan and inform
efforts to improve or maintain the
quality of service offered to the public.
If this information is not collected, vital
feedback from customers and
stakeholders on the NIH’s services will
be unavailable.
The NIH will only submit a collection
for approval under this generic
clearance if it meets the following
conditions:
• The collections are voluntary;
E:\FR\FM\21NON1.SGM
21NON1
]]>Agencies
[Federal Register Volume 79, Number 225 (Friday, November 21, 2014)]
[Notices]
[Pages 69499-69500]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-27636]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-Day Comment Request; Application for
Collaboration With the Therapeutic Development Branch (TDB), Division
of Preclinical Innovation (DPI), National Center for Advancing
Translational Sciences (NCATS)
Summary: In compliance with the requirement of Section
3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity
for public comment on proposed data collection projects, the National
Center for Advancing Translational Sciences (NCATS), National
Institutes of Health (NIH), will publish periodic summaries of proposed
projects to be submitted to the Office of Management and Budget (OMB)
for review and approval.
Written comments and/or suggestions from the public and affected
agencies are invited on one or more of the following points: (1)
Whether the proposed collection of information is necessary for the
proper performance of the function of the agency, including whether the
information will have practical utility; (2) The accuracy of the
agency's estimate of the burden of the proposed collection of
information, including the validity of the methodology and assumptions
used; (3) Ways to enhance the quality, utility, and clarity of the
information to be collected; and (4) Ways to minimize the burden of the
collection of information on those who are to respond, including the
use of appropriate automated, electronic, mechanical, or other
technological collection techniques or other forms of information
technology.
To Submit Comments and for Further Information: To obtain a copy of
the data collection plans and instruments, submit comments in writing,
or request more information on the proposed project, contact: Dr. Nora
Yang, Therapeutic Development Branch, DPI, NCATS, NIH, 9800 Medical
Center Drive, Building B, Rockville, MD 20850, or call non-toll-free
number (301) 217-1077, or Email your request, including your address
to: TRND@mail.nih.gov. Formal requests for additional plans and
[[Page 69500]]
instruments must be requested in writing.
Comment Due Date: Comments regarding this information collection
are best assured of having their full effect if received within 60 days
of the date of this publication.
Proposed Collection: Application for Collaboration with the
Therapeutic Development Branch (TDB), Division of Preclinical
Innovation (DPI), National Center for Advancing Translational Sciences
(NCATS), 0925-0658, Expiration Date 06/30/2015--EXTENSION, National
Center for Advancing Translational Sciences (NCATS), National
Institutes of Health (NIH).
Need and Use of Information Collection: The Therapeutic Development
Branch (TDB) provides opportunities to partner with and gain access to
a variety of programs delivering assay development, screening, hit-to-
lead chemistry, lead optimization, chemical biology studies, drug
development capabilities, expertise, and clinical/regulatory resources
in a collaborative environment, with the goal of moving promising
therapeutics into human clinical trials for both common and
specifically rare and/or neglected diseases. The TDB uses an
application and evaluation process to select collaborators. Selected
investigators provide the drug project starting points and ongoing
biological/disease expertise throughout the project. The application
and evaluation process is necessary to determine amount and quality of
current data, select meritorious projects for adoption, and to serve as
a basis for determining specific scientific gaps to be filled.
OMB approval is requested for 3 years. There are no costs to
respondents other than their time. The estimated annualized burden
hours are 510.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Form name Number of responses per per response Total annual
respondents respondent (in hours) burden hour
----------------------------------------------------------------------------------------------------------------
TDB Project Information Template................ 170 1 1 170
Online Collaborator Solicitation (TRND)......... 100 1 1 100
Online Collaborator Solicitation (BrIDGs)....... 70 1 1 70
Solicitation Instructions (TRND)................ 100 1 1 100
Solicitation Instructions (BrIDGs).............. 70 1 1 70
----------------------------------------------------------------------------------------------------------------
Dated: October 29, 2014.
M. Janis Mullaney,
Associate Director for Administration, NCATS, NIH.
[FR Doc. 2014-27636 Filed 11-20-14; 8:45 am]
BILLING CODE 4140-01-P
